Deciphering the divergent roles of progestogens in breast cancer.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 27885264.
- Also identified by DOI 10.1038/nrc.2016.116.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Most breast cancers are driven by oestrogen receptor-α. Anti-oestrogenic drugs are the standard treatment for these breast cancers; however, treatment resistance is common, necessitating new therapeutic strategies. Recent preclinical and historical clinical studies support the use of progestogens to activate the progesterone receptor (PR) in breast cancers. However, widespread controversy exists regarding the role of progestogens in this disease, hindering the clinical implementation of PR-targeted therapies. Herein, we present and discuss data at the root of this controversy and clarify the confusion and misinterpretations that have consequently arisen. We then present our view on how progestogens may be safely and effectively used in treating breast cancer.
Medical subject headings
- Breast Neoplasms
- Estrogen Receptor alpha
- Progestins
- Receptors, Progesterone